Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of camrelizumab in malignant solid tumors
ChiCTR2100048691Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in Non-hematologic malignancy and hepatocellular carcinoma (HCC), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: progression-free survival, objective remission rate and 3 more. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
Non-hematologic malignancyhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100048691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048691.